Sunil Srivastava, MD
Ophthalmology · Cleveland, OHNPI 1225094378
Payments from drug & device makers
Across 341 payments — averaging $8259.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2M
- Eyepoint US, Inc.$338K
- Novartis$247K
- Bausch & Lomb Americas Inc.$82K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$76K
- Carl Zeiss Meditec, Inc.$13K
- plus $58K from 14 others
Across 41 payments — averaging $2498.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$59K
- Novartis$37K
- F. Hoffmann-la Roche AG$4K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 71 | $2,002,292 |
| Eyepoint US, Inc. | 23 | $338,147 |
| Novartis | 22 | $247,442 |
| Bausch & Lomb Americas Inc. | 92 | $81,838 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 69 | $76,025 |
| Carl Zeiss Meditec, Inc. | 10 | $13,048 |
| Merck | 9 | $9,512 |
| AbbVie(2 entities) | 6 | $9,422 |
| Sanofi US Services Inc. | 1 | $7,950 |
| Bausch Health US, LLC | 4 | $6,553 |
| Regeneron Healthcare Solutions, Inc. | 10 | $5,629 |
| Genentech USA, Inc. | 2 | $4,710 |
| Ocular Therapeutix, Inc. | 4 | $4,522 |
| Kala Pharmaceuticals, Inc. | 1 | $4,500 |
| Gilead | 6 | $3,378 |
| Apellis Pharmaceuticals, Inc. | 5 | $553 |
| Alcon | 1 | $395 |
| Alimera Sciences, Inc. | 3 | $329 |
| Dompe US, Inc. | 1 | $85 |
| Optos PLC | 1 | $38 |
How this compares
$2,816,369 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Cleveland
- Justis EhlersCleveland$5M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- Yasha ModiCleveland$883K
- Douglas RheeCleveland$461K
- Faruk OrgeCleveland$419K
- William DuppsCleveland$220K
- Marc AbramsCleveland$189K
- Shree KurupCleveland$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.